Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation.

Glycogen synthase kinase 3beta (GSK3beta) reportedly has opposing roles, repressing Wnt/beta-catenin signaling on the one hand but maintaining cell survival and proliferation through the NF-kappaB pathway on the other. The present investigation was undertaken to clarify the roles of GSK3beta in human cancer. In colon cancer cell lines and colorectal cancer patients, levels of GSK3beta expression and amounts of its active form were higher in tumor cells than in their normal counterparts; these findings were independent of nuclear accumulation of beta-catenin oncoprotein in the tumor cells. Inhibition of GSK3beta activity by phosphorylation was defective in colorectal cancers but preserved in non-neoplastic cells and tissues. Strikingly, inhibition of GSK3beta activity by chemical inhibitors and its expression by RNA interference targeting GSK3beta induced apoptosis and attenuated proliferation of colon cancer cells in vitro. Our findings demonstrate an unrecognized role of GSK3beta in tumor cell survival and proliferation other than its predicted role as a tumor suppressor, and warrant proposing this kinase as a potential therapeutic target in colorectal cancer.

[1]  J. Thrasher,et al.  Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. , 2003, Molecular cancer therapeutics.

[2]  A. Duval,et al.  Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines , 2001, Oncogene.

[3]  S. Fuchs,et al.  Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB in colorectal cancer , 2004 .

[4]  T. Minamoto,et al.  Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. , 2002, Gastroenterology.

[5]  R. Bhat,et al.  GSK3β Signalling: Casting a Wide Net in Alzheimer’s Disease , 2002, Neurosignals.

[6]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[7]  P. Greengard,et al.  Pharmacological inhibitors of glycogen synthase kinase 3. , 2004, Trends in pharmacological sciences.

[8]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. , 2000, Nature.

[9]  Chawnshang Chang,et al.  Suppression of Androgen Receptor-mediated Transactivation and Cell Growth by the Glycogen Synthase Kinase 3β in Prostate Cells* , 2004, Journal of Biological Chemistry.

[10]  J. Waxman,et al.  Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth , 2004, Oncogene.

[11]  Michel Goedert,et al.  GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.

[12]  R. Schwabe,et al.  Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[13]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[14]  J. Woodgett,et al.  Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. , 2002, Advances in cancer research.

[15]  M. Pincus,et al.  Conformation-dependent phosphorylation of p53. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Leggett,et al.  Emerging concepts in colorectal neoplasia. , 2002, Gastroenterology.

[17]  E. T. Gawlinski,et al.  The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. , 2003, Cancer research.

[18]  B. Modan,et al.  Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment , 1998, Medical oncology.

[19]  A. Adjei,et al.  Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.

[20]  B. Rigas,et al.  Insulin Resistance and Its Contribution to Colon Carcinogenesis , 2003, Experimental biology and medicine.

[21]  M. K. Doeberitz,et al.  Reduction of β-Catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin Is Caused by an Increased Stabilization of Phosphorylated β-Catenin , 2003 .

[22]  M. Kitamura,et al.  Identification of a five-pass transmembrane protein family localizing in the Golgi apparatus and the ER. , 2003, Biochemical and biophysical research communications.

[23]  P. Polakis.  The oncogenic activation of beta-catenin. , 1999, Current opinion in genetics & development.

[24]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[25]  Zijie Sun,et al.  Phosphatidylinositol 3-Kinase/Akt Stimulates Androgen Pathway through GSK3β Inhibition and Nuclear β-Catenin Accumulation* , 2002, The Journal of Biological Chemistry.

[26]  Paul Polakis,et al.  The oncogenic activation of β-catenin , 1999 .

[27]  G A Colditz,et al.  Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. , 1999, Journal of the National Cancer Institute.